ArticleArchives of microbiology2026
TOR kinase inhibition reverses azole resistance in Candida auris by targeting heme biosynthesis.
Article in Archives of microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Antimicrobial resistance is a global menace, and multidrug-resistant fungal pathogens pose a serious global health threat. With limited numbers of antifungals available and the emergence of pan-drug-resistant strains, combating fungal infections has become increasingly challenging. Iron homeostasis is known to influence antifungal susceptibility. However, the role of heme, an iron-containing cofactor, in drug resistance remains poorly understood. We investigated the contribution of heme dynamics to acquired azole tolerance and evaluated the therapeutic potential of targeting heme biosynthesis and homeostasis in Candida auris (C. auris). We show that Hemin confers stress-specific protection in C. auris, rescuing growth and biofilm defects caused by Fluconazole (Flc) and the TOR kinase inhibitor Torin2. Transcriptomic analysis revealed that Torin2 in C. auris induces autophagy, represses global translation, and redirects glutamate metabolic flux. Growth complementation assays and quantitative gene expression experiments confirmed that glutamate metabolic flux is redirected towards glutamine biosynthesis via Gln1 activation rather than TCA-cycle participation via Gdh2. This and Hem1 downregulation lead to reduced heme biosynthesis by Torin2. Flc, however, increases heme biosynthesis. Flc binds to the heme moiety of Erg11; hence, increased heme biosynthesis helps buffer Flc. Hemin or 5-ALA supplementation partially rescued growth and restored porphyrin and heme levels. Notably, scavenged heme from Sheep Blood increased MICs for azoles and terbinafine, demonstrating heme-mediated drug tolerance. Importantly, combined Torin2 and Flc treatment reduces growth by downregulating heme exchange and drug efflux, highlighting a potential combinatorial strategy to overcome azole resistance in C. auris. This study highlights the crucial link between the TOR pathway and heme and ergosterol metabolism, which contributes to drug resistance. It proposes targeting heme dynamics as a promising avenue for combination antifungal therapies, potentially improving clinical outcomes against C. auris and other resistant fungal pathogens.
Indexed as
Identifiers
42742738What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.